When finance must become a decision engine
How finance functions can move from control and reporting toward adaptive planning, stronger insight and faster enterprise decisions.
Read articlePharmaceuticals and biotechnology enter late 2026 with scientific innovation continuing across advanced modalities and major therapeutic categories while commercial portfolios face substantial pressure from patent expiries, generics and biosimilars. Pricing and market access remain central strategic constraints, and geopolitical and supply-chain exposure has become more prominent in portfolio decisions. Capital is consequently becoming more discriminating about which platforms, assets and indications deserve continued investment. The industry must improve the conversion of scientific opportunity into differentiated medicines and sustainable economics rather than assuming that pipeline breadth alone will replace mature revenue pools.
Focus
Strategic Challenges
Strategic Impacts
Observed Patterns
Strategic Challenges
Strategic Impacts
Observed Patterns
Industry Challenge
Pharmaceutical and biotechnology companies continue to face high development costs, long timelines and significant clinical attrition while payers and governments increase scrutiny of price and value. Patent expiries create additional pressure on established portfolios, and competition is intensifying in attractive therapeutic areas. The challenge is to raise R&D productivity without sacrificing scientific quality. Companies need sharper portfolio choices, better use of external innovation and stronger evidence strategies, while preparing manufacturing and commercial scale-up.
Future Outlook
The future life-sciences model will combine increasingly data-rich biology with AI, advanced diagnostics and more precise therapeutic design. AI can improve target discovery, trial design and knowledge management, while digital twins and predictive methods may reduce experimentation in selected parts of development and manufacturing. The strategic impact will depend on data quality and scientific integration rather than software alone. Companies that connect internal R&D with biotech ecosystems, real-world evidence and flexible manufacturing can shorten learning cycles and sharpen choices.
Market Outlook
Life sciences markets are showing stronger momentum in 2026, supported by positive clinical readouts, renewed M&A and investor interest in differentiated pipelines. AI is becoming more embedded in discovery and development, but capital remains selective and the quality of underlying science still drives value. Large pharmaceutical companies continue to use acquisitions and partnerships to refresh portfolios ahead of patent losses, while pricing and market-access policy remain material sources of uncertainty. The market favors differentiated assets with scalable manufacturing.
POV
Our approach
Our approach� begins with the unmet need and scientific logic underlying a therapeutic opportunity, then connects clinical differentiation with development risk, competitive intensity, regulatory pathways and commercial access. We examine assets as part of a portfolio because capital committed to one platform or indication changes the options available elsewhere. Patent life, lifecycle strategy, manufacturing and potential partnering are incorporated into the same economic view. This allows pipeline and business-development choices to reflect expected strategic value rather than scientific promise or headline market size in isolation.
The data and estimates presented are indicative and intended for illustrative purposes. Actual outcomes may vary based on each company’s specific context, market conditions, operating model, implementation choices, and the quality and consistency of execution, including actions undertaken by the client.
Keypillars
Explore the key pillars that define this capability and shape how we create focused, measurable business impact.
Portfolio economics
Examines R&D productivity, pipeline value, pricing, patents, commercialization, and lifecycle economics across life-sciences portfolios
Innovation system
Connects discovery, clinical development, regulatory approval, manufacturing, market access, and commercialization across the sector
Scientific transition
Tracks biotechnology, precision medicine, AI-enabled discovery, new modalities, and regulatory evolution reshaping industry competition
Strategic Framework
Assess therapeutic areas, pipelines, platforms, patients, providers, payers, regulation, and competitive assets
Monitor trials, approvals, launches, patents, competitor pipelines, reimbursement, and scientific developments
Choose therapeutic, pipeline, market, partnership, manufacturing, and commercialization priorities
Examine science, clinical progress, modalities, patents, regulation, reimbursement, and technology convergence
Evaluate pipeline quality, portfolio, evidence, capabilities, market access, manufacturing, and partnerships
Test clinical, regulatory, adoption, pricing, competition, patent, and portfolio scenarios
How we help
We help pharmaceutical and biotechnology companies assess therapeutic markets, pipeline priorities, product and platform economics and opportunities for licensing, partnerships or M&A. Support can extend to portfolio strategy, market access, geographic expansion, commercialization, operating-model transformation and investment prioritization across R&D and manufacturing. We focus on the decisions linking science with enterprise value: where differentiation is sufficient, which assets deserve additional capital and how portfolios should evolve as patents and competitive standards change.
Explore our FAQs
Find answers to the most common questions about this service, including key features, processes, and practical considerations. Explore our FAQs for additional insights and guidance.
Related services
Discover related services and capabilities designed to help organizations connect strategic priorities, address complex challenges, and unlock value across the business.
Articles
How finance functions can move from control and reporting toward adaptive planning, stronger insight and faster enterprise decisions.
Read articleHow infrastructure capacity, asset lifecycle choices and delivery ecosystems increasingly shape growth, resilience and competitive advantage.
Read articleFocus
Catastrophe exposure, changing customer expectations and AI adoption are reshaping underwriting, claims and the economics of insurance operations.
With financing conditions stabilizing, asset value increasingly depends on cash-flow quality, sector fundamentals and active operating capability.
Strategic challenges
The challenge is balancing commercial demand, sovereign incentives and export restrictions across extremely capital-intensive technology cycles.
The challenge is restoring volume and relevance without surrendering margin through permanent promotion or excessive portfolio complexity.